Skip to main content

Profile of common inflammatory markers in treatment-naïve patients with systemic rheumatic diseases

Clinical Rheumatology volume 39, pages 2899–2906 (2020)Cite this article

Abstract

Objectives

To evaluate and compare the clinical implications of common inflammatory markers in systemic rheumatic diseases (SRDs).

Method

We investigated the profiles of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and white blood cell (WBC) count in treatment-naïve patients with SRDs, osteoarthritis and pneumonia diagnosed at Seoul National University Hospital during 2004–2016. SRDs included rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), ankylosing spondylitis (AS), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM) and adult-onset Still’s disease (AOSD). Associations between inflammatory markers were evaluated using Pearson’s correlation and regression analysis. ROC curve analysis was performed to examine the predictive value of inflammatory markers for SRD diagnosis.

Results

We identified a total of 1191 patients. Leukocytosis was present in < 20% SRD patients. There was marked variability in ESR and CRP levels among different SRDs. The highest mean CRP levels (mean ± SD, mg/dL) were observed in AOSD (11.3 ± 7.9), followed by RA (2.0 ± 3.3), IIM (1.8 ± 3.5), SLE (1.5 ± 3.1), SSc (0.6 ± 1.3) and AS (0.08 ± 0.1). Mean ESR (mm/h) was also highest in AOSD (71.2 ± 31.0), followed by SLE (47.3 ± 34.2), RA (45.5 ± 30.6), IIM (40.8 ± 24.8) and SSc (27.8 ± 26.0). All SRDs showed significant positive correlations between ESR and CRP: greatest in RA (r = 0.53, p < 0.001) and weakest in SLE (r = 0.20, p = 0.03). WBC correlated weakly with CRP but not with ESR in most SRDs. While the AUC for WBC count was less than that of ESR or CRP, the AUC for ESR and CRP were similar in SRD. The optimal cuff-off values for inflammatory markers predicting SRD were within or slightly above the normal limit.

Conclusions

ESR, CRP and WBC are not always elevated in treatment-naïve patients with SRD. Individual SRDs have a unique profile of inflammatory markers. However, routine inflammatory markers should still be interpreted with caution when diagnosing and assessing disease activity in those with SRD.

Key Points
•Leukocytosis and elevation of ESR and CRP are not always present in all systemic rheumatic diseases.
•Inflammatory markers are often dissociated and they are not specific for disease diagnosis.
•Better biomarkers, which measure disease-specific local and systemic inflammation, are needed.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

Data availability

The data that support the results of this study are available from the corresponding author, JKP, upon request.

References

  1. Zweifach BW, Grant L, McCluskey RT (2014) The inflammatory process. Academic Press, New York

    Google Scholar 

  2. Gruys E, Toussaint M, Niewold T, Koopmans S (2005) Acute phase reaction and acute phase proteins. J Zhejiang Univ Sci B 6:1045–1056

    Article  CAS  Google Scholar 

  3. Heinrich PC, Castell JV, Andus T (1990) Interleukin-6 and the acute phase response. Biochem J 265:621–636

    Article  CAS  Google Scholar 

  4. Feldman M, Aziz B, Kang GN, Opondo MA, Belz RK, Sellers C (2013) C-reactive protein and erythrocyte sedimentation rate discordance: frequency and causes in adults. Transl Res 161:37–43

    Article  CAS  Google Scholar 

  5. Keenan R, Swearingen C, Yazici Y (2008) Erythrocyte sedimentation rate and C-reactive protein levels are poorly correlated with clinical measures of disease activity in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis patients. Clin Exp Rheumatol 26:814–819

    PubMed  CAS  Google Scholar 

  6. Syed KM, Pinals RS (1996) Leukocytosis in rheumatoid arthritis. J Clin Rheumatol 2:197–202

    Article  CAS  Google Scholar 

  7. Go DJ, Lee EY, Lee EB, Song YW, Konig MF, Park JK (2016) Elevated erythrocyte sedimentation rate is predictive of interstitial lung disease and mortality in dermatomyositis: a Korean retrospective cohort study. J Korean Med Sci 31:389–396. https://doi.org/10.3346/jkms.2016.31.3.389

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

    Article  CAS  Google Scholar 

  9. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581

    Article  Google Scholar 

  10. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725–1725

    Article  CAS  Google Scholar 

  11. Linden SVD, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. Arthritis Rheum 27:361–368

    Article  Google Scholar 

  12. Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA, Carreira PE (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum 65:2737–2747

    Article  Google Scholar 

  13. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, Kashiwazaki S, Tanimoto K, Matsumoto Y, Ota T (1992) Preliminary criteria for classification of adult Still’s disease. J Rheumatol 19:424–430

    PubMed  CAS  Google Scholar 

  14. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis. N Engl J Med 292:344–347

    Article  CAS  Google Scholar 

  15. Siemons L, ten Klooster PM, Vonkeman HE, van Riel PL, Glas CA, van de Laar MA (2014) How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis. BMC Musculoskelet Disord 15:368

    Article  CAS  Google Scholar 

  16. Lakoski SG, Cushman M, Criqui M, Rundek T, Blumenthal RS, D'Agostino RB Jr, Herrington DM (2006) Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J 152:593–598

    Article  CAS  Google Scholar 

  17. Ranganath VK, Elashoff DA, Khanna D, Park G, Peter JB, Paulus HE (2005) Age adjustment corrects for apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset of seropositive rheumatoid arthritis in younger and older patients. J Rheumatol 32:1040–1042

    PubMed  Google Scholar 

  18. Isaacs A, Lindenmann J (1957) Virus interference. I. The interferon. Pro R Soc Lond B Biol Sci 147:258–267

    Article  CAS  Google Scholar 

  19. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD (1998) How cells respond to interferons. Annu Rev Biochem 67:227–264

    Article  CAS  Google Scholar 

  20. Dinarello CA (2000) Proinflammatory cytokines. Chest 118:503–508

    Article  CAS  Google Scholar 

  21. Pinsky MR, Vincent J-L, Deviere J, Alegre M, Kahn RJ, Dupont E (1993) Serum cytokine levels in human septic shock: relation to multiple-system organ failure and mortality. Chest 103:565–575

    Article  CAS  Google Scholar 

  22. Holub M, Lawrence DA, Andersen N, Davidová A, Beran O, Marešová V, Chalupa P (2013) Cytokines and chemokines as biomarkers of community-acquired bacterial infection. Mediat Inflamm 2013:190145. https://doi.org/10.1155/2013/190145

    Article  CAS  Google Scholar 

  23. McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A (2015) Type I interferons in infectious disease. Nat Rev Immunol 15:87–103. https://doi.org/10.1038/nri3787

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. O'Shea JJ, Ma A, Lipsky P (2002) Cytokines and autoimmunity. Nat Rev Immunol 2:37

    Article  CAS  Google Scholar 

  25. Maria AT, Le Quellec A, Jorgensen C, Touitou I, Riviere S, Guilpain P (2014) Adult onset Still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev 13:1149–1159. https://doi.org/10.1016/j.autrev.2014.08.032

    Article  PubMed  CAS  Google Scholar 

  26. Schett G, Elewaut D, McInnes IB, Dayer J-M, Neurath MF (2013) How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med 19:822–824

    Article  CAS  Google Scholar 

  27. Moulis G, Sommet A, Lapeyre-Mestre M, Montastruc J-L (2014) Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database. Rheumatology 53:1864–1871. https://doi.org/10.1093/rheumatology/keu214

    Article  PubMed  CAS  Google Scholar 

  28. Gaitonde S, Samols D, Kushner I (2008) C-reactive protein and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 59:1814–1820

    Article  CAS  Google Scholar 

  29. Honig S, Gorevic P, Weissmann G (1977) C-reactive protein in systemic lupus erythematosus. Arthritis Rheum 20:1065–1070

    Article  CAS  Google Scholar 

  30. Becker G, Waldburger M, Hughes G, Pepys M (1980) Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann Rheum Dis 39:50–52

    Article  CAS  Google Scholar 

  31. Hill AS (1951) C-reactive protein in the chronic rheumatic diseases. Lancet 2:807–811

    Article  CAS  Google Scholar 

  32. Aringer M (2019) Inflammatory markers in systemic lupus erythematosus. J Autoimmun. https://doi.org/10.1016/j.jaut.2019.102374

  33. Greenberg SA (2010) Type 1 interferons and myositis. Arthritis Res Ther 12:1–7. https://doi.org/10.1186/ar2885

    Article  CAS  Google Scholar 

  34. Greenberg SA (2010) Dermatomyositis and type 1 interferons. Curr Rheumatol Rep 12:198–203. https://doi.org/10.1007/s11926-010-0101-6

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Salajegheh M, Kong SW, Pinkus JL, Walsh RJ, Liao A, Nazareno R, Amato AA, Krastins B, Morehouse C, Higgs BW, Jallal B, Yao Y, Sarracino DA, Parker KC, Greenberg SA (2010) Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 67:53–63. https://doi.org/10.1002/ana.21805

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Park JK, Gelber AC, George M, Danoff SK, Qubti MA, Christopher-Stine L (2013) Pulmonary impairment, not muscle injury, is associated with elevated ESR in the idiopathic inflammatory myopathies. Rheumatology (Oxford) 52:1336–1338. https://doi.org/10.1093/rheumatology/ket162

    Article  Google Scholar 

  37. Gupta P, Friberg LE, Karlsson MO, Krishnaswami S, French J (2010) A semi-mechanistic model of CP-690,550-induced reduction in neutrophil counts in patients with rheumatoid arthritis. J Clin Pharmacol 50:679–687

    Article  CAS  Google Scholar 

  38. Tanaka Y, McInnes IB, Taylor PC, Byers NL, Chen L, de Bono S, Issa M, Macias WL, Rogai V, Rooney TP (2018) Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis. Arthritis Rheum 70:1923–1932

    Article  CAS  Google Scholar 

  39. Smith E, Jorgensen A, Beresford M (2017) Do classic blood biomarkers of JSLE identify active lupus nephritis? Evidence from the UK JSLE cohort study. Lupus 26:1212–1217

    Article  CAS  Google Scholar 

  40. Schäfer VS, Weiß K, Krause A, Schmidt WA (2018) Does erythrocyte sedimentation rate reflect and discriminate flare from infection in systemic lupus erythematosus? Correlation with clinical and laboratory parameters of disease activity. Clin Rheumatol 37:1835–1844

    Article  Google Scholar 

  41. Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA (2018) Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis 77:840–847

    PubMed  PubMed Central  CAS  Google Scholar 

  42. Muangchan C, Harding S, Khimdas S, Bonner A, Group CSR, Baron M, Pope J (2012) Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res (Hoboken) 64:1405–1414

    Article  CAS  Google Scholar 

  43. Yayla ME, İlgen U, Okatan İE, UsluYurteri E, Torgutalp M, Dinçer ABK, Gülöksüz EGA, Sezer S, Turgay TM, Kınıklı G (2020) Association of simple hematological parameters with disease manifestations, activity, and severity in patients with systemic sclerosis. Clin Rheumatol 39:77–8

Download references

Author information

Affiliations

  1. Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul, 03080, South Korea

    Min Jung Kim, Eun Bong Lee, Yeong Wook Song & Jin Kyun Park

Authors
  1. Min Jung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eun Bong Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yeong Wook Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jin Kyun Park
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JKP conceived and designed the study. MJK acquired the data, did statistical analysis and drafted the manuscript. All authors interpreted the data, critically revised the manuscript for important intellectual content and approved the final version of the manuscript.

Corresponding author

Correspondence to Jin Kyun Park.

Ethics declarations

Disclosures

None.

Ethics approval

The study complied with the Declaration of Helsinki and was approved by the Institutional Review Board of Seoul National University Hospital (H-1702-064-831).

Consent to participate

The requirement for informed consent was waived due to the retrospective nature of study.

Consent to publication

Not applicable

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM1

(DOCX 16 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kim, M.J., Lee, E.B., Song, Y.W. et al. Profile of common inflammatory markers in treatment-naïve patients with systemic rheumatic diseases. Clin Rheumatol 39, 2899–2906 (2020). https://doi.org/10.1007/s10067-020-05049-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-020-05049-9

Keywords

  • CRP
  • Cytokine
  • ESR
  • Inflammatory marker
  • Rheumatic disease
  • WBC